Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Generic Makers Permitted to Use Original Makers' ADR Data without Permission
April 28, 2008
- Half of Hepatitis C Patients who Stop IFN Treatment Do so Because of Cost
April 28, 2008
- 70% of Doctors Permit Substitution for Oral Vitamins
April 28, 2008
- Janssen to Launch 4 New Products per Year
April 28, 2008
- Will Generics Take Off? (1)
April 28, 2008
- Takeda Bio Development Center to Apply for 2 Products by 2010
April 28, 2008
- GENERICS NEWS IN BRIEF
April 28, 2008
- JHSF Proposes Support of Alliances
April 21, 2008
- JPMA Calls For Creation of Clinical Trials Centers
April 21, 2008
- Global Market for Drugs for Alzheimer's Disease to Expand to US$9.2 Bil.: Datamonitor
April 21, 2008
- R&D NEWS IN BRIEF（1）
April 21, 2008
- BUSINESS NEWS IN BRIEF
April 21, 2008
- R&D NEWS IN BRIEF（2）
April 21, 2008
- Orchid of India Announces Entry into Japanese Market
April 21, 2008
- NEW PRODUCTS
April 21, 2008
- Generic Makers to Embark on Mergers, Tie-ups: Mr Sawai
April 21, 2008
- NCC to Take Full Advantage of New System to Provide Advanced Healthcare to More Patients
April 21, 2008
- Doctors Should Collect Information Themselves when Using Generics: Prof. Ogata
April 21, 2008
- Further Spread of Hepatitis C Viral Infections Unlikely: Chugai Seminar
April 21, 2008
- Korosho to Punish Healthcare Providers Who Don't Try to Use More Generics: Mr Nakagaki
April 21, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…